About this trial
In most clinical instances, direct laryngoscopy and endotracheal intubation is performed after a set time (generally 60 seconds) following the administration of a neuromuscular (NM) blocking agent, rocuronium. Although the average onset time is 60 seconds, clinical studies show a standard deviation around the mean onset time of 10-20 seconds, meaning that a significant number of patients do not achieve complete NM blockade by 60 seconds. Given the above noted variability, complete NM blockade may not be achieved in 60 seconds in a significant percentage of patients, resulting in more problematic direct laryngoscopy and endotracheal intubation. Various studies have shown a higher incidence of perioperative respiratory events and postoperative concerns (sore throat, vocal cord injury) when NM blockade is not complete prior to endotracheal intubation.
This study aims to use the TetraGraph monitor to clearly identify onset times of rocuronium. Additionally, whenever feasible based on the clinical needs of the case, recovery times after the single dose of rocuronium will be recorded.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
consenting American Society of Anesthesiologists (ASA) Physical Status 1-4 patients
undergoing a surgical procedure with general anesthesia and requiring the administration of rocuronium
Disqualifiers
Patients with history of a progressive or degenerative peripheral neurologic or neuropathic disorder
Patients undergoing a surgical procedure in which neuromuscular blockade is not required
Edematous patients
Trial design
Single group
Treatments tested in this trial
TetraGraph
DeviceA monitor that provides an electrical stimulation of the peripheral nerve and directly measures the amplitude of the evoked response of the muscles, thereby providing a quantitative and automatic measurement of muscle response to a stimulus using electromyography (EMG).
Treatment groups
Trial outcomes
Primary outcomes
Onset time
Amount of time from administration of rocuronium to the monitor reading 0 twitches.
Secondary outcomes
Recovery time
Amount of time from administration of reversal medication (sugammadex or neostigmine) to monitor reading 4 twitches.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: